The store will not work correctly when cookies are disabled.
N-(1-(4-fluorophenyl)ethyl)-5-methyl-3-(pyridin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine
ID: ALA5177479
PubChem CID: 168272604
Max Phase: Preclinical
Molecular Formula: C20H18FN5
Molecular Weight: 347.40
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1cc(NC(C)c2ccc(F)cc2)n2ncc(-c3ccccn3)c2n1
Standard InChI: InChI=1S/C20H18FN5/c1-13-11-19(25-14(2)15-6-8-16(21)9-7-15)26-20(24-13)17(12-23-26)18-5-3-4-10-22-18/h3-12,14,25H,1-2H3
Standard InChI Key: KDLJLCJWRSXODQ-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
-2.6187 2.8552 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9041 3.2675 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1922 2.8555 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1922 2.0304 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.9023 1.6185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6187 2.0267 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9023 0.7934 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2350 0.3086 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.4899 -0.4758 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.3147 -0.4758 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.5695 0.3086 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4306 0.4791 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.1216 -0.1338 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1302 -0.9149 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9354 -1.0911 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.9182 0.0796 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.1489 -1.8877 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.5656 -2.4709 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2308 -2.2574 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4444 -1.4609 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2387 -1.2488 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8221 -1.8321 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6112 -2.6252 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8164 -2.8431 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.7792 -3.2675 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6187 -1.6187 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
5 7 1 0
8 7 2 0
8 9 1 0
9 10 1 0
10 11 2 0
11 7 1 0
8 12 1 0
13 12 2 0
14 13 1 0
15 14 2 0
9 15 1 0
13 16 1 0
15 17 1 0
17 18 1 0
18 19 1 0
20 19 2 0
21 20 1 0
22 21 2 0
23 22 1 0
24 23 2 0
19 24 1 0
18 25 1 0
22 26 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 347.40 | Molecular Weight (Monoisotopic): 347.1546 | AlogP: 4.41 | #Rotatable Bonds: 4 |
Polar Surface Area: 55.11 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 3.18 | CX LogP: 3.45 | CX LogD: 3.45 |
Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.59 | Np Likeness Score: -2.02 |
References
1. Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW.. (2022) Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators., 61 [PMID:35123006] [10.1016/j.bmcl.2022.128607] |
2. Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW.. (2022) Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators., 61 [PMID:35123006] [10.1016/j.bmcl.2022.128607] |